The NADH-dependent Enoyl-ACP reductase (InhA) of Mycobacterium tuberculosis has been shown to be the primary target of the frontline drug isoniazid (INH). However, INH must be first activated by katG gene, mutations in which have mediated resistance to INH. Recently, direct inhibitors of InhA have been reported. Using a structure-based approach, we have identified a tripeptide inhibitor with the sequence WYW, which is 100 times more potent than the existing inhibitors. It is therefore, a potential lead compound for the development of new anti-TB drugs.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1747-0285.2008.00722.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in Nonsmall Cell Lung Cancer Patients With EGFR Mutation.
Clin Respir J
January 2025
Division of Pulmonology, Department of Internal Medicine, Seoul St. Mary's Hospital, Catholic University of Korea, Seoul, Republic of Korea.
Introduction: The provision of treatment for epidermal growth factor receptor (EGFR)-mutated nonsmall cell lung cancer (NSCLC) patients has increased in Korea. However, multicenter studies on the clinicopathologic dataset and treatment outcomes, using a large-scale dataset, have not been conducted. The current study is a prospective and retrospective multicenter observational cohort study that registers all stages of EGFR-mutated NSCLC patients.
View Article and Find Full Text PDFPeroxiredoxin 1-Toll-like receptor 4-p65 axis inhibits receptor activator of nuclear factor kappa-B ligand-mediated osteoclast differentiation.
iScience
December 2024
Department of Biological Sciences and Biotechnology, Chungbuk National University, Cheongju, Chungbuk, Republic of Korea.
Peroxiredoxin 1 (PRDX1), an intracellular antioxidant enzyme, has emerged as a regulator of inflammatory responses via Toll-like receptor 4 (TLR4) signaling. Despite this, the mechanistic details of the PRDX1-TLR4 axis and its impact on osteoclast differentiation remain elusive. Here, we show that PRDX1 suppresses RANKL-induced osteoclast differentiation.
View Article and Find Full Text PDFTrifluoromethylcinnamanilides - Effective dual inhibitors of Mycobacterium smegmatis and Plasmodium falciparum.
Bioorg Chem
January 2025
Faculty of Chemistry, Biochemistry and Pharmacy, National University of San Luis, IMIBIO-CONICET, Ejército de los Andes 950, 5700 San Luis, Argentina. Electronic address:
Article Synopsis
- Researchers synthesized eighteen new compounds called 2-trifluoromethylcinnamanilides and studied their effects against Mycobacterium smegmatis and Plasmodium falciparum, with promising results for certain substituted variants.
- The most effective compounds against M. smegmatis were those with specific trifluoromethyl substitutions, while several anilides also showed strong activity against P. falciparum, with some comparable to chloroquine.
- Initial cytotoxicity tests revealed that some compounds had toxic effects, but others did not, and further studies indicated that two compounds were stable and did not interfere with liver metabolism, enhancing their potential as dual-action antimicrobials.
Effects of Tegoprazan, Potassium-Competitive Acid Blocker, on the Gastric Emptying and Postprandial Symptoms in Healthy Humans.
Dig Dis Sci
November 2024
Department of Internal Medicine, College of Medicine, Ewha Womans University, 1071 Anyangcheon-Ro, Yangcheon-Gu, Seoul, 07985, Republic of Korea.
Background And Aims: Proton pump inhibitors are potent gastric acid inhibitors. However, they may worsen symptoms such as postprandial fullness and early satiation by reducing gastric emptying (GE). This study aims to evaluate the effects of tegoprazan, a new potassium-competitive acid blocker, on GE and dyspeptic symptoms.
View Article and Find Full Text PDFSynthesis, Biological Evaluation, Molecular Docking Studies and ADMET Prediction of Oxindole-Based Hybrids for the Treatment of Tuberculosis.
Curr Comput Aided Drug Des
October 2024
Parul Institute of Pharmacy & Research, Parul University Department of Pharmacology Vadodara India.
Article Synopsis
- Tuberculosis (TB) remains a major global health issue, causing an estimated 1.4 million deaths in 2019, highlighting the need for new treatment options due to existing drug resistance and side effects.
- This study focuses on the development of oxindole-based hybrids as potential InhA inhibitors to combat Mycobacterium tuberculosis, involving both anti-mycobacterial activity evaluations and molecular docking studies to understand drug interactions.
- Among the synthesized compounds, 8b demonstrated strong anti-mycobacterial activity and a favorable safety profile, showing promise as a new treatment and adhering to established drug-likeness criteria.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!